Wang P, Luo S, Shen C, Yu Z, Nie Z, Li Z, Wen J, Li M, Cao X
Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China.
Nan Fang Yi Ke Da Xue Xue Bao. 2022 Apr 20;42(4):575-583. doi: 10.12122/j.issn.1673-4254.2022.04.14.
To investigate the therapeutic effect of Epothilone D on traumatic optic neuropathy (TON) in rats.
Forty-two SD rats were randomized to receive intraperitoneal injection of 1.0 mg/kg Epothilone D or DMSO (control) every 3 days until day 28, and rat models of TON were established on the second day after the first administration. On days 3, 7, and 28, examination of flash visual evoked potentials (FVEP), immunofluorescence staining and Western blotting were performed to examine the visual pathway features, number of retinal ganglion cells (RGCs), GAP43 expression level in damaged axons, and changes of Tau and pTau-396/404 in the retina and optic nerve.
In Epothilone D treatment group, RGC loss rate was significantly decreased by 19.12% (=0.032) on day 3 and by 22.67% (=0.042) on day 28 as compared with the rats in the control group, but FVEP examination failed to show physiological improvement in the visual pathway on day 28 in terms of the relative latency of N2 wave (=0.236) and relative amplitude attenuation of P2-N2 wave (=0.441). The total Tau content in the retina of the treatment group was significantly increased compared with that in the control group on day 3 ( < 0.001), showing a consistent change with ptau-396/404 level. In the optic nerve axons, the total Tau level in the treatment group was significantly lower than that in the control group on day 7 (=0.002), but the changes of the total Tau and pTau-396/404 level did not show an obvious correlation. Epothilone D induced persistent expression of GAP43 in the damaged axons, detectable even on day 28 of the experiment.
Epothilone D treatment can protect against TON in rats by promoting the survival of injured RGCs, enhancing Tau content in the surviving RGCs, reducing Tau accumulation in injured axons, and stimulating sustained regeneration of axons.
探讨埃坡霉素D对大鼠外伤性视神经病变(TON)的治疗作用。
将42只SD大鼠随机分为两组,每3天腹腔注射1.0 mg/kg埃坡霉素D或二甲基亚砜(对照),直至第28天,在首次给药后第2天建立TON大鼠模型。在第3、7和28天,进行闪光视觉诱发电位(FVEP)检查、免疫荧光染色和蛋白质印迹法,以检测视觉通路特征、视网膜神经节细胞(RGC)数量、受损轴突中GAP43表达水平以及视网膜和视神经中Tau和pTau-396/404的变化。
与对照组大鼠相比,埃坡霉素D治疗组在第3天RGC损失率显著降低19.12%(P=0.032),在第28天降低22.67%(P=0.042),但FVEP检查显示在第28天视觉通路在N2波相对潜伏期(P=0.236)和P2-N2波相对波幅衰减(P=0.441)方面未显示出生理改善。治疗组视网膜中总Tau含量在第3天与对照组相比显著增加(P<0.001),与ptau-396/404水平变化一致。在视神经轴突中,治疗组总Tau水平在第7天显著低于对照组(P=0.002),但总Tau和pTau-396/404水平变化未显示明显相关性。埃坡霉素D诱导受损轴突中GAP43持续表达,甚至在实验第28天仍可检测到。
埃坡霉素D治疗可通过促进受损RGC存活、增加存活RGC中Tau含量、减少受损轴突中Tau积累以及刺激轴突持续再生来保护大鼠免受TON损伤。